Home > Riviste > International Angiology > Fascicoli precedenti > International Angiology 2020 April;39(2) > International Angiology 2020 April;39(2):112-7

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE  VENOUS DISEASE Editor’s choice • Freefree

International Angiology 2020 April;39(2):112-7

DOI: 10.23736/S0392-9590.20.04272-8

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Frequency and predictors of chemotherapy-associated venous thromboembolism: the prospective PREVENT study

Stavros K. KAKKOS 1, Eleni ARNAOUTOGLOU 2, 3, Ioannis A. TSOLAKIS 1, Athanasios GIANNOUKAS 4, Christos A. PAPADIMITRIOU 5, Nikolaos KENTEPOZIDIS 6, Ioannis BOUKOVINAS 7, Haralabos P. KALOFONOS 8, Nicos LABROPOULOS 9, Miltiadis MATSAGKAS 4

1 Department of Vascular Surgery, University of Patras Medical School, Patras, Greece; 2 Department of Anesthesiology, University of Thessaly, Larissa, Greece; 3 Department of Anesthesiology, University of Ioannina, Ioannina, Greece; 4 Department of Vascular Surgery, University of Thessaly, Larissa, Greece; 5 Unit of Oncology, Second Department of Surgery, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, Greece; 6 Department of Medical Oncology, 251 Air Force Hospital, Athens, Greece, 7 Department of Medical Oncology, Bioclinic Hospital, Thessaloniki, Greece; 8 Division of Oncology, Department of Medicine, University of Patras Medical School, Patras, Greece; 9 Division of Vascular Surgery, Department of Surgery, Stony Brook University, Stony Brook, NY, USA



BACKGROUND: Our knowledge on the burden of symptomatic and asymptomatic venous thromboembolism (VTE) in patients with cancer undergoing chemotherapy is limited. The aim of our study was to prospectively investigate the frequency of symptomatic VTE and asymptomatic deep vein thrombosis of the lower limbs among cancer patients undergoing chemotherapy.
METHODS: We studied 231 patients (164 men) with pancreatic (N.=36), lung (N.=136), ovarian (N.=32) or prostate (N.=27) cancer receiving first line (N.=192, 83.1%) or adjuvant chemotherapy, followed-up for 3-6 months.
RESULTS: Some 17 patients were diagnosed with VTE, either asymptomatic detected on leg ultrasound (N.=7) or symptomatic (N.=10). The total frequency of VTE was 10.3% (17/165 with follow-up). Pancreatic cancer had the highest frequency of VTE (4/25, 16%) followed by ovarian (3/26, 11.5%) and lung cancer (10/94, 10.6%). There was no statistically significant difference in VTE rates among cancer types (P=0.36). VTE occurred more frequently in the presence of metastases (13/85, 15.3% vs. 4/80, 5.0%, for the remainder, P=0.03, OR 3.4). In the subgroup of patients receiving first line treatment, VTE occurred more frequently in patients with metastases (13/84, 15.5% vs. 2/53, 3.8%, for the remainder, P=0.033). In patients with pancreatic, lung or ovarian cancer receiving first line treatment, VTE occurred more frequently in patients with metastatic disease (19.1% vs. 4.0%, for the remainder, P=0.015).
CONCLUSIONS: VTE occurrence in this real-world patient cohort was high, reaching almost 20% in certain groups, like those with disseminated pancreatic, lung or ovarian cancer receiving first-line chemotherapy. Furthermore, VTE occurs mostly as a symptomatic event, being likely a result of the prothrombotic state of malignancy.


KEY WORDS: Neoplasms; Chemotherapy, adjuvant; Venous thromboembolism

inizio pagina